

Lucie Skarydova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3703926/publications.pdf>

Version: 2024-02-01

25
papers

407
citations

759233

12
h-index

752698

20
g-index

25
all docs

25
docs citations

25
times ranked

535
citing authors

#	ARTICLE	IF	CITATIONS
1	Small molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases. <i>Medicinal Research Reviews</i> , 2022, 42, 1822-1855.	10.5	11
2	Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17 β -HSD10 with Implications to Alzheimer's Disease Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2059.	4.1	14
3	RNase T1 Refolding Assay for Determining Mitochondrial Cyclophilin D Activity: A Novel <i>In Vitro</i> Method Applicable in Drug Research and Discovery. <i>Biochemistry</i> , 2020, 59, 1680-1687.	2.5	3
4	Initial characterization of human DHRS1 (SDR19C1), a member of the short-chain dehydrogenase/reductase superfamily. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 185, 80-89.	2.5	7
5	The identification of new substrates of human DHRS7 by molecular modeling and in vitro testing. <i>International Journal of Biological Macromolecules</i> , 2017, 105, 171-182.	7.5	4
6	AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types. <i>Natural Product Communications</i> , 2017, 12, 1934578X1701200.	0.5	5
7	Human DHRS7, promising enzyme in metabolism of steroids and retinoids?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 112-119.	2.5	17
8	Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties. <i>Molecular and Cellular Biochemistry</i> , 2016, 411, 35-42.	3.1	6
9	Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier. <i>Chemico-Biological Interactions</i> , 2015, 234, 169-177.	4.0	2
10	Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment. <i>Journal of Natural Products</i> , 2015, 78, 2666-2674.	3.0	31
11	Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). <i>Chemico-Biological Interactions</i> , 2015, 234, 178-187.	4.0	13
12	Purification and reconstitution of human membrane-bound DHRS7 (SDR34C1) from Sf9 cells. <i>Protein Expression and Purification</i> , 2014, 95, 44-49.	1.3	8
13	Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 250-258.	2.5	27
14	Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. <i>Chemico-Biological Interactions</i> , 2014, 207, 52-57.	4.0	23
15	Deeper Insight into the Reducing Biotransformation of Bupropion in the Human Liver. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 177-184.	2.2	38
16	Imbalance in redox system of rat liver following permethrin treatment in adolescence and neonatal age. <i>Xenobiotica</i> , 2013, 43, 1103-1110.	1.1	18
17	Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand. <i>Journal of Separation Science</i> , 2013, 36, 1176-1184.	2.5	2
18	Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone <i>in vitro</i> . <i>Xenobiotica</i> , 2013, 43, 346-354.	1.1	33

#	ARTICLE	IF	CITATIONS
19	A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK. <i>Drug Metabolism Letters</i> , 2013, 6, 174-181.	0.8	5
20	Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. <i>Drug Metabolism Reviews</i> , 2012, 44, 173-191.	3.6	33
21	Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. <i>Chemico-Biological Interactions</i> , 2011, 191, 66-74.	4.0	29
22	Enzyme Stereospecificity as a Powerful Tool in Searching for New Enzymes. <i>Current Drug Metabolism</i> , 2010, 11, 547-559.	1.2	6
23	AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. <i>Chemico-Biological Interactions</i> , 2009, 178, 138-144.	4.0	56
24	Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. <i>Toxicology</i> , 2009, 264, 52-60.	4.2	12
25	Ubiquinol-10/lipids ratios in consecutive patients with different angiographic findings. <i>Clinica Chimica Acta</i> , 2007, 380, 133-138.	1.1	4